Positron emission tomography (PET) is a modern non-invasive imaging technique for quantification of radioactivity in vivo. It involves the intravenous injection of a positron-emitting radiopharmaceutical, waiting to allow for systemic distribution, and then scanning to detect and quantification of patterns of radiopharmaceutical accumulation in the body.
As with SPECT imaging, PET scan data can be reconstructed and displayed as a three dimensional image. This is in contrast to scintigraphy, which yields planar data which can only be used to create a two dimensional image.
Although the physiologic information afforded by PET and SPECT imaging is invaluable, the quality of obtained data is poor/noisy and limits imaging spatial resolution. For this reason, PET and SPECT scans are often combined with CT imaging, allowing correlation between functional and anatomical imaging ("hybrid imaging").
A radiolabelled biological compound such as 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is injected intravenously.
Uptake of this compound followed by further breakdown occurs in the cells. Tumor cells have a high metabolic rate, and hence this compound is also metabolized by tumor cells.
FDG is metabolized to FDG-6-phosphate which cannot be further metabolized by tumor cells, and hence it accumulates and concentrates in tumor cells. This accumulation is detected and quantified.
The positron emitting isotope administered to the patient undergoes β+ decay in the body, with a proton being converted to a neutron, a positron (the anti-particle of the electron, sometimes referred to as a β+ particle) and a neutrino. The positron travels a short distance and annihilates with an electron. The annihilation reaction results in the formation of two high energy photons which travel in diametrically opposite directions.
Each photon has an energy of 511 keV. Two detectors at opposite ends facing each other detect these two photons traveling in opposite directions, and the radioactivity is localized somewhere along a line between the two detectors. This is referred to as the line of response.
- fasting for 4-6 hours
- blood glucose level <150 mg/dl
- avoid strenuous activity 24 hours prior to imaging
- avoid speech 20 minutes prior to imaging
- the scan is carried out 60 minutes post-injection of FDG
In cases of fusion imaging such as PET-CT, the whole body CT scan is conducted first, followed by the whole-body PET scan and subsequently the two sets of images are co-registered.
A standard uptake value (SUV) is calculated at the end of the study i.e. ratio of activity per unit mass tissue to injected dose per unit body mass.
Motion artefacts result in an inaccurate anatomical coregistration of the CT and PET studies. Whilst the distance (2-3 mm) the positron travels before annihilation and the detector element size results in relatively poor spatial resolution.
Physiological muscle uptake usually appears symmetrically and diffusely on PET imaging.
When combined with CT, the CT imaging can be used to generate an attenuation map which is used to correct the PET imaging for attenuation. This attenuation correction can add a number of further artefacts.
- artefacts related to respiratory motion causes the 'mushroom effect' where an artefact is sometimes seen in the lung bases because of the different phases of respiratory motion
- implants and prostheses
- metallic implants such as joint prostheses can create significant artefact on PET images as the attenuation correction cannot deal with/correct for markedly high densities
- CT field of view is limited whereas PET field of view is usually larger; if patients are scanned with arms by their side this can lead to abnormal reconstruction of the images
Normal physiological uptake
- brain tissue
- skeletal muscle, especially after strenuous activity and laryngeal muscles following speech
- gastrointestinal tract, e.g. intestinal wall
- genitourinary tract: FDG is excreted via the renal system and passes into the collecting systems
- brown fat
- thymus 4
- bone marrow 5
False-positive FDG uptake
This may occur due to the following conditions:
- granulomatous disease
- surgical changes
- foreign body reaction
- excessive bowel uptake with metformin therapy
- inflammation (although at times e.g. evaluating for vasculitis, this may be the finding of interest)
- detection, staging, response to treatment
- differentiation between radiation necrosis and recurrence
- identification of hibernating myocardium
- 1.Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics. 2004;24 (2): 523-43. doi:10.1148/rg.242025724 - Pubmed citation
- 2.Votaw JR. The AAPM/RSNA physics tutorial for residents. Physics of PET. Radiographics. 1995;15 (5): 1179-90. doi:10.1148/radiographics.15.5.7501858 - Pubmed citation
- 3. Grainger & Allison's diagnostic radiology essentials. Churchill Livingstone. ISBN:0702034487. Read it at Google Books - Find it at Amazon
- 4. Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics. 2004;24 (6): 1611-6. doi:10.1148/rg.246045701 - Pubmed citation
- 5. Kostakoglu L, Hardoff R, Mirtcheva R et-al. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24 (5): 1411-31. doi:10.1148/rg.245035725 - Pubmed citation